0000000000226300

AUTHOR

R. Kaiser

showing 16 related works from this author

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

2014

Background: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy.Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained con…

Malevirus strainResistanceHIV InfectionsDrug resistanceTHERAPYNucleoside Reverse Transcriptase InhibitorANTIRETROVIRAL DRUG-RESISTANCE0302 clinical medicineMedical microbiologyGenotypeMedicine and Health SciencesPrevalenceHIV Infection030212 general & internal medicineUNITED-KINGDOMPhylogeny0303 health sciencesCommunicable diseaseTransmission (medicine)adultvirus mutationUPDATED RECOMMENDATIONSvirus transmission3. Good healthEuropeInfectious Diseasesfemalerisk factorvirus resistanceFemaleNAIVE PATIENTSSOCIETY-USA PANELResearch ArticleHumanAdultmedicine.medical_specialtyGenotypeAnti-HIV AgentsVirusArticle03 medical and health sciencesSDG 3 - Good Health and Well-beingmaleMOLECULAR EPIDEMIOLOGYDrug Resistance Viralmedicineproteinase inhibitorHumansTransmissioncontrolled studyhumanmolecular phylogeny030304 developmental biologynonhumanMUTATIONSbusiness.industryAnti-HIV Agentnucleotide sequencenonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionVirologymajor clinical studyunindexed sequenceParasitology3121 General medicine internal medicine and other clinical medicineMutationHIV-1business
researchProduct

Fragmentation of accelerated 2.1 GeV/nucleon12C,14N and16O Ions in nuclear emulsion

1975

The inelastic-interaction mean free path and fragmentation parameters in nuclear emulsion of accelerated 2.1 GeV/nucleon12C,14N and16O have been determined. The discrimination of the targets has been achieved with a new method. The global results obtained for the three ions have been compared with theM-group of the cosmic radiation.

Nuclear physicsPhysicsFragmentation (mass spectrometry)Mean free pathAstrophysics::High Energy Astrophysical PhenomenaHigh Energy Physics::ExperimentCosmic rayNuclear emulsionNuclear ExperimentIonIl Nuovo Cimento A
researchProduct

The Green function and SU(3) breaking in Kl3 decays

2005

18 páginas, 1 figura, 1 tabla.-- arXiv:hep-ph/0503108v3

Física1/N ExpansionChiral lagrangiansQCDCaltech Library Services
researchProduct

Measurement of the proton and deuteron structure functions, F2p and F2d, and of the ratio

1997

The muon-proton and muon-deuteron inclusive deep inelastic scattering cross sections were measured in the kinematic range 0.002 < x < 0.60 and 0.5 < Q(2) < 75 GeV2 at incident muon energies of 90, 120, 200 and 280 GeV. These results are based on the full data set collected by the New Muon Collaboration, including the data taken with a small angle trigger. The extracted values of the structure functions F-2(p) and F-2(d) are in good agreement with those from other experiments. The data cover a sufficient range of y to allow the determination of the ratio of the longitudinally to transversely polarised virtual photon absorption cross sections, R = sigma(L)/sigma(T), for 0.002 < x < 0.12. The …

Nuclear physicsPhysicsNuclear and High Energy PhysicsParticle physicsMuonProtonDeuteriumVirtual particlePerturbative QCDSigmaHigh Energy Physics::ExperimentDeep inelastic scatteringElectron scatteringNuclear Physics B
researchProduct

Quark and gluon distributions and $\alpha_{s}$ from nucleon structure functions at low $x$

1993

Abstract The Q2 dependence of the structure functions F2p and F2d recently measured by the NMC is compared with the predictions of perturbative QCD at next-to-leading order. Good agreement is observed, leading to accurate determinations of the quark and gluon distributions in the range 0.008 ⩽ × ⩽ 0.5. The strong coupling constant is measured from the low x data; the result agrees with previous determinations.

QuarkNuclear and High Energy PhysicsParticle physicsHigh Energy Physics::Latticedeep inelastic scattering: muon deuteronmuon deuteron: deep inelastic scatteringPARTON DENSITIESJet (particle physics)530CROSS-SECTIONSNuclear physicsnumerical calculations: interpretation of experimentsstrong interaction: coupling constant90: 280 GeVDEEP INELASTIC-SCATTERING; LEADING ORDER; QUANTUM CHROMODYNAMICS; PERTURBATION-THEORY; PARTON DENSITIES; CROSS-SECTIONS; FREEDOM; MSBAR; JET; NMCdeep inelastic scattering: muon pp: structure functionNMCCoupling constantQuantum chromodynamicsPhysicsQUANTUM CHROMODYNAMICSLEADING ORDERHigh Energy Physics::Phenomenologydeuteron: structure functiongluon: momentum spectrumperturbation theory: higher-orderPerturbative QCDDeep inelastic scatteringquark: momentum spectrumFREEDOMGluondependence: momentum transferJETMSBARmuon p: deep inelastic scatteringPERTURBATION-THEORYDEEP INELASTIC-SCATTERINGHigh Energy Physics::Experimentcoupling constant: strong interactionNucleonParticle Physics - Experiment
researchProduct

Measurement of azimuthal asymmetries associated with deeply virtual Compton scattering on a longitudinally polarized deuterium target

2010

Azimuthal asymmetries in exclusive electroproduction of a real photon from a longitudinally polarized deuterium target are measured with respect to target polarization alone and with respect to target polarization combined with beam helicity and/or beam charge. The asymmetries appear in the distribution of the real photons in the azimuthal angle $\phi$ around the virtual photon direction, relative to the lepton scattering plane. The asymmetries arise from the deeply virtual Compton scattering process and its interference with the Bethe-Heitler process. The results for the beam-charge and beam-helicity asymmetries from a tensor polarized deuterium target with vanishing vector polarization ar…

Nuclear and High Energy Physics/dk/atira/pure/sustainabledevelopmentgoals/affordable_and_clean_energyEVOLUTION KERNELS010308 nuclear & particles physicsGENERALIZED PARTON DISTRIBUTIONS; IMPACT PARAMETER SPACE; ELECTRON STORAGE-RING; EVOLUTION KERNELS; HERA; SPIN; NUCLEON; QCDHERAIMPACT PARAMETER SPACEFOS: Physical sciencesQCD01 natural sciencesHigh Energy Physics - ExperimentHigh Energy Physics - Experiment (hep-ex)ELECTRON STORAGE-RINGSPINGENERALIZED PARTON DISTRIBUTIONS0103 physical sciencesddc:530High Energy Physics::ExperimentSDG 7 - Affordable and Clean EnergyNUCLEON010306 general physics
researchProduct

Measurements of $R^{d}-R^{p}$ and $R^{Ca}-R^{C}$ in deep inelastic muon scattering

1992

Results are presented on the difference in R, the ratio of longitudinally to transversely polarised virtual photon absorption cross sections, for the deuteron and the proton. They are obtained by c ...

Nuclear and High Energy PhysicsProtonmuon nucleus: deep inelastic scatteringNuclear Theorypolarization: longitudinaldeep inelastic scattering: muon deuteronVirtual particlecross section: ratiophoton: absorptionElementary particlemuon deuteron: deep inelastic scattering530Nuclear physicsabsorption: photondeep inelastic scattering: muon ppolarization: transverseHIGH STATISTICS MEASUREMENT; R=SIGMA-L/SIGMA-T; HIGH Q2Nuclear ExperimentAbsorption (electromagnetic radiation)deep inelastic scattering: muon nucleus90: 200: 280 GeVPhysicsHIGH STATISTICS MEASUREMENTMuoncalciumScatteringcarbonstructure function: ratioR=SIGMA-L/SIGMA-TCERN SPSlongitudinal: polarizationParticle scatteringDeuteriummuon p: deep inelastic scatteringHIGH Q2Physics::Accelerator Physicstransverse: polarizationAtomic physicsParticle Physics - Experimentexperimental results
researchProduct

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe

2016

Transmitted human immunodeficiency virus drug resistance in Europe is stable at around 8%. The impact of baseline mutation patterns on susceptibility to antiretroviral drugs should be addressed using clinical guidelines. The impact on baseline susceptibility is largest for nonnucleoside reverse transcriptase inhibitors.

MaleHuman immunodeficiency virus 1EtravirineRNA directed DNA polymerase inhibitordarunavirHIV InfectionsSettore MED/42 - Igiene Generale E Applicata:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Salud públicageneticsInhibidores de proteasas:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings]atazanavirmedia_commontransmission:Geographicals::Geographic Locations::Europe [Medical Subject Headings]3. Good healthmicrobial sensitivity testpriority journalEurope ; HIV-1 ; antiretroviral therapy ; drug resistance ; transmissionHIV/AIDSlamivudineReverse Transcriptase Inhibitors/pharmacologyanti human immunodeficiency virus agentDrugMicrobiology (medical)medicine.medical_specialtyantiviral susceptibility:Phenomena and Processes::Genetic Phenomena::Genetic Variation::Mutation [Medical Subject Headings]media_common.quotation_subjectantiretroviral therapy030106 microbiologyHIV Infections/drug therapy:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Reverse Transcriptase Inhibitors [Medical Subject Headings]Microbial Sensitivity TestsRILPIVIRINEArticleEFAVIRENZ03 medical and health sciencestransmitted drug resistanceSDG 3 - Good Health and Well-beingHumansTransmissionhuman:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance [Medical Subject Headings]REVERSE-TRANSCRIPTASE INHIBITORSRilpivirinaINTEGRASEMUTATIONSabacavirmajor clinical studyVirologyInfecciones por VIHRegimenAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Medicine (all); Microbiology (medical); Infectious DiseaseschemistryDrug resistance:Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds 1-Ring::Oxazines::Benzoxazines [Medical Subject Headings]MutationHIV-10301 basic medicinenevirapineDrug resistanceCommunicable diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Confidence Intervals [Medical Subject Headings]chemistry.chemical_compoundantiviral therapyINFECTIONMedicine and Health SciencesPrevalence:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings]ViralNon-U.S. Gov'tReverse-transcriptase inhibitorantiretrovirus agentResearch Support Non-U.S. Gov'tMedicine (all)Human immunodeficiency virus infected patientMiddle AgedvirologyPREVALENCEAntiretroviral therapyEncuestas y CuestionariosANTIRETROVIRAL TREATMENTEuropeInfectious DiseasesHIV-1/drug effectsHIV Protease Inhibitors/pharmacologyRilpivirineReverse Transcriptase Inhibitors:Diseases::Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections [Medical Subject Headings]FemaleHIV drug resistancemedicine.drugAdultHuman immunodeficiency virus proteinase inhibitor:Chemicals and Drugs::Organic Chemicals::Nitriles::Rilpivirine [Medical Subject Headings]EfavirenzAnti-HIV AgentsResearch SupportResistencia a medicamentosSettore MED/17 - MALATTIE INFETTIVEantiviral resistanceInternal medicineAnti-HIV Agents/pharmacologyDrug Resistance ViralJournal Articlemedicine:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors [Medical Subject Headings]abacavir plus lamivudineEuropa (Continente)Antiretroviral therapy; Drug resistance; Europe; HIV-1; Transmission; Adult; Anti-HIV Agents; Drug Resistance Viral; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Microbiology (medical); Infectious DiseasesemtricitabinenonhumanIntervalos de confianzadrug resistanceMutaciónAntiretroviral therapy; Drug resistance; Europe; HIV-1; Transmissionbusiness.industryHIVpredictionInhibidores de la transcriptasa inversaHIV Protease InhibitorsHuman immunodeficiency virus 1 infectiontenofovirINDIVIDUALSDrug Resistance Viral/geneticsBenzoxazinasETRAVIRINEdrug effects3121 General medicine internal medicine and other clinical medicinePrevalenciabusiness
researchProduct

Measurement of the Charge-Averaged Elastic Lepton-Proton Scattering Cross Section by the OLYMPUS Experiment

2020

Physical review letters 126(16), 162501 (1-6) (2021). doi:10.1103/PhysRevLett.126.162501

ProtonPhysics::Instrumentation and Detectorselectromagnetic [calorimeter]elastic scatteringGeneral Physics and AstronomyElectronmomentum transfer dependence01 natural sciencesEconomicaelectromagnetic form factorsDESY LabNuclear Experiment (nucl-ex)Nuclear ExperimentNuclear ExperimentPhysicsElastic scatteringLuminosity (scattering theory)Form factor (quantum field theory)elastic scattering [cross section]recoil [p]beam [positron]target [hydrogen]electromagnetic [form factor]electron-proton scatteringSocio-culturaleFOS: Physical sciences530electron p: scatteringNuclear physicsCross section (physics)PE2_2PE2_10103 physical sciencesform factor [p]p: recoilddc:530cross section: elastic scattering010306 general physicsPE2_3hydrogen: targetNuclear Physicspositron p: scatteringAmbientalepositron-proton scatteringDESYscattering [electron p]form factor: electromagneticscattering [positron p]positron: beamcalorimeter: electromagneticp: form factorPhysics::Accelerator PhysicsHigh Energy Physics::Experimentspectrometerexperimental resultsLeptonPhysical Review Letters
researchProduct

Exclusive ϱ0 and φ muoproduction at large Q2

1994

Abstract Exclusive ϱ 0 and φ muoproduction on deuterium, carbon and calcium has been studied in the kinematic range 2 Q 2 2 and 40 Q 2 dependence of the cross sections, the transverse momentum distributions for the vector mesons, the decay angular distributions and, in the case of the ϱ 0 , nuclear effects. The data for 0 production are compatible with a diffractive mechanism. The distinct features of φ production are a smaller cross section and less steep p t 2 distributions than those for the 0 mesons.

PhysicsNuclear and High Energy PhysicsRange (particle radiation)Particle physicsMesonHADRONSMUON SCATTERINGTRANSVERSE-MOMENTUMPROTONQCD530Nuclear physicsCross section (physics)RATIOAngular distributionDeuteriumTransverse momentumDEEP INELASTIC-SCATTERING; MUON SCATTERING; TRANSVERSE-MOMENTUM; PROTON; HADRONS; RATIO; QCDDEEP INELASTIC-SCATTERINGNuclear Physics B
researchProduct

The A dependence of the nuclear structure function ratios

1996

Results are presented for six nuclei from Be to Pb on the structure function ratios F-2(A)/F-2(C)(X) and their A dependence in deep inelastic muon scattering at 200 GeV incident: muon energy. The data cover the kinematic range 0.01 < x < 0.8 with Q(2) ranging from 2 to 70 GeV2. The A dependence of nuclear structure function ratios is parametrised and compared to various models.

PhysicsNuclear and High Energy PhysicsMuonINELASTIC MUON SCATTERING; R=SIGMA-L/SIGMA-T; ELECTRON-SCATTERING; CROSS-SECTIONS; CHARGE-DENSITY; A-DEPENDENCEScatteringStructure functionNuclear structureCharge densityCHARGE-DENSITYFunction (mathematics)R=SIGMA-L/SIGMA-TCROSS-SECTIONSNuclear physicsELECTRON-SCATTERINGINELASTIC MUON SCATTERINGA-DEPENDENCERange (statistics)High Energy Physics::ExperimentAtomic physicsNuclear ExperimentElectron scattering
researchProduct

Precision measurement of the structure function ratiosF 2 He /F 2 D ,F 2 C /F 2 D andF 2 Ca /F 2 D

1991

We present the structure function ratiosF2He/F2D,F2C/F2D andF2Ca/F2D measured in deep inelastic muon-nucleus scattering at an incident muon momentum of 200 GeV. The kinematic range 0.0035<x<0.65 and 0.5<Q2<90 GeV2 is covered. At lowx the three ratios are significantly smaller than unity and the size of the depletion grows with decreasingx and increasing mass numberA. At intermediatex the ratios show an enhancement of about 2% above unity for C/D and Ca/D, possibly less for He/D. There are indications of someQ2 dependence in the Ca/D data. The integrals of the structure function differencesF2A−F2D are discussed.

PhysicsMomentum (technical analysis)MuonPhysics and Astronomy (miscellaneous)ScatteringStructure functionchemistry.chemical_elementElementary particle530Particle accelerationchemistryAtomic physicsEngineering (miscellaneous)Particle Physics - ExperimentHeliumZeitschrift f�r Physik C Particles and Fields
researchProduct

Precision measurement of structure function ratios for $^{6}$Li, $^{12}$C and $^{40}$Ca

1992

The structure function ratiosF2C/F2Li,F2Ca/F2Li andF2Ca/F2C were measured in deep inelastic muonnucleus scattering at an incident muon energy of 90 GeV, covering the kinematic range 0.0085<x<0.6 and 0.8<Q2<17GeV2. The sensitivity of the nuclear structure functions to the size and mean density of the target nucleus is discussed.

PhysicsRange (particle radiation)MuonPhysics and Astronomy (miscellaneous)ScatteringNuclear structureElementary particleNuclear physicsmedicine.anatomical_structureDeuteriummedicineAtomic physicsEngineering (miscellaneous)NucleusElectron scatteringParticle Physics - Experiment
researchProduct

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive …

2012

Background: The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission. While compensatory mutations increase fitness during treatment, their presence may also modulate viral fitness and virulence in absence of therapy and major resistance mutations. We previously designed a modeling technique that quantifies genotypic footprints of in vivo treatment selective pressure, including both drug …

AdultMalelcsh:Immunologic diseases. AllergyAnti-HIV AgentseducationVirulenceHIV InfectionsDrug resistanceBiologySettore MED/42 - Igiene Generale E ApplicataViruspolymorphism03 medical and health sciencesViral ProteinsSDG 3 - Good Health and Well-beingVirologyGenotypeDrug Resistance Viraldrug-naivemedicineHumansProspective Studies030304 developmental biology0303 health sciencesPolymorphism Genetic030306 microbiologyResearchproteaseViral LoadVirologyReverse transcriptase3. Good healthCD4 Lymphocyte CountDrug-naïveInfectious Diseases3121 General medicine internal medicine and other clinical medicineImmunologybiology.proteinHIV-1FemaleAntibodylcsh:RC581-607Viral loadHIV-1 infected patientmedicine.drugPeptide HydrolasesRetrovirology
researchProduct

Limited cross-border infections in patients newly diagnosed with HIV in Europe

2013

Background: International travel plays a role in the spread of HIV-1 across Europe. It is, however, not known whether international travel is more important for spread of the epidemic as compared to endogenous infections within single countries. In this study, phylogenetic associations among HIV of newly diagnosed patients were determined across Europe.Results: Data came from the SPREAD programme which collects samples of newly diagnosed patients that are representative for national HIV epidemics. 4260 pol sequences from 25 European countries and Israel collected in 2002-2007 were included.We identified 457 clusters including 1330 persons (31.2% of all patients). The cluster size ranged bet…

MaleEpidemiologyHuman immunodeficiency virus (HIV)Human immunodeficiency virus 1HIV Infectionsmedicine.disease_causeVirologie généralephylogenySettore MED/42 - Igiene Generale E ApplicataMen who have sex with menEMERGENCE0302 clinical medicineMedicine and Health SciencesMedicineInfection controlCluster Analysis030212 general & internal medicineIsraelPathologie maladies infectieusestravelPhylogeny0303 health sciencesMolecular EpidemiologyTravelTransmission (medicine)articlevirus transmissionIMMUNODEFICIENCY-VIRUS TYPE-13. Good healthPeer reviewEuropefemaleInfectious DiseasesSUBTYPE BDRUG-RESISTANT HIV-1RNA Viralmale homosexualAdultstructural geneMolecular Sequence DataNewly diagnosedClusters03 medical and health sciencesmaleSDG 3 - Good Health and Well-beingMOLECULAR EPIDEMIOLOGYSWITZERLANDVirologygeographic distributionHumansTransmissionIn patienthuman030304 developmental biologynonhumanMolecular epidemiologybusiness.industryResearchhigh risk populationVirologie médicalenucleotide sequenceSequence Analysis DNAHuman immunodeficiency virus 1 infectionVirologymajor clinical studyunindexed sequence3121 General medicine internal medicine and other clinical medicineHIV-1businessEurope HIV-1 Transmission ClustersDemographycluster analysis
researchProduct

Measurement of the spin-dependent structure function g1(x) of the deuteron

1993

We report on the first measurement of the spin-dependent structure function g1d of the deuteron in the deep inelastic scattering of polarised muons off polarised deuterons, in the kinematical range 0.006&lt;x&lt;0.6, 1 GeV2&lt;Q2&lt;30 GeV2. The first moment, Γ1d=sh{phonetic}01 g1d dx=0.023±0.020 (stat.) ± 0.015 (syst.), is smaller than the prediction of the Ellis-Jaffe sum rules. Using earlier measurements of g1p, we infer the first moment of the spin-dependent neutron structure function g1n. The difference Γ1p-Γ1n=0.20 ±0.05 (stat.) ± 0.04 (syst.) agrees with the prediction of the Bjorken sum rule, Γ1p-Γ1n=0.191 ±0.002.

deuteron: polarized targetNuclear and High Energy PhysicsINELASTIC E-P; POLARIZED PROTONS; SUM-RULE; SCATTERING; ELECTROPRODUCTION; ASYMMETRYINELASTIC E-PProtonpolarized target: deuterondeep inelastic scattering: muon deuteronstructure function: spinmuon deuteron: deep inelastic scatteringSUM-RULE530Nuclear physicsINELASTIC E-P; POLARIZED PROTONS; SUM-RULE; SCATTERING; ELECTROPRODUCTION; ASYMMETRY; MODELTheoryofComputation_ANALYSISOFALGORITHMSANDPROBLEMCOMPLEXITYSCATTERINGNeutronpolarized beam: muonSpin-½PhysicsQuantum chromodynamicsspin: structure functionMuonScatteringdeuteron: structure functionELECTROPRODUCTIONnucleon: structure functionCERN SPSDeep inelastic scatteringmomentmagnetic spectrometer: experimental resultsPOLARIZED PROTONSapprox. 100 GeVASYMMETRYSum rule in quantum mechanicsmuon: polarized beamParticle Physics - ExperimentPhysics Letters B
researchProduct